FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 120 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... September 18, 2019 The Unique Challenges Teenagers and Young Adults With Cancer Face: An... January 4, 2021 Does Sugar Feed Cancer? March 19, 2021 First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with... February 14, 2023 Load more HOT NEWS Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... FDA Says Breast Implant Cancer Risk Is Not Enough to Warrant... A New Study Suggests Screen Time Might Not Be The Worst...
